Trial · NCT05601882
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (Baseline - Week 16) | STARTED | Dupilumab (Period 1) | 462 | |
| Period 1 (Baseline - Week 16) | STARTED | Upadacitinib (Period 1) | 458 | |
| Period 1 (Baseline - Week 16) | STARTED | Dupilumab -> Upadacitinib (Period 2) | 0 | |
| Period 1 (Baseline - Week 16) | STARTED | Upadacitinib -> Upadacitinib 30 mg (Period 2) | 0 | |
| Period 1 (Baseline - Week 16) | COMPLETED | Dupilumab (Period 1) | 423 | |
| Period 1 (Baseline - Week 16) | COMPLETED | Upadacitinib (Period 1) | 418 | |
| Period 1 (Baseline - Week 16) | COMPLETED | Dupilumab -> Upadacitinib (Period 2) | 0 | |
| Period 1 (Baseline - Week 16) | COMPLETED | Upadacitinib -> Upadacitinib 30 mg (Period 2) | 0 | |
| Period 1 (Baseline - Week 16) | NOT COMPLETED | Dupilumab (Period 1) | 39 | |
| Period 1 (Baseline - Week 16) | NOT COMPLETED | Upadacitinib (Period 1) | 40 | |
| Period 1 (Baseline - Week 16) | NOT COMPLETED | Dupilumab -> Upadacitinib (Period 2) | 0 | |
| Period 1 (Baseline - Week 16) | NOT COMPLETED | Upadacitinib -> Upadacitinib 30 mg (Period 2) | 0 | |
| Period 2 (Week 16 - Week 32) | STARTED | Dupilumab (Period 1) | 0 | |
| Period 2 (Week 16 - Week 32) | STARTED | Upadacitinib (Period 1) | 0 | |
| Period 2 (Week 16 - Week 32) | STARTED | Dupilumab -> Upadacitinib (Period 2) | 208 | |
| Period 2 (Week 16 - Week 32) | STARTED | Upadacitinib -> Upadacitinib 30 mg (Period 2) | 147 | |
| Period 2 (Week 16 - Week 32) | COMPLETED | Dupilumab (Period 1) | 0 | |
| Period 2 (Week 16 - Week 32) | COMPLETED | Upadacitinib (Period 1) | 0 | |
| Period 2 (Week 16 - Week 32) | COMPLETED | Dupilumab -> Upadacitinib (Period 2) | 198 | |
| Period 2 (Week 16 - Week 32) | COMPLETED | Upadacitinib -> Upadacitinib 30 mg (Period 2) | 131 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05601882/flow